Deleobuvir

Drug Profile

Deleobuvir

Alternative Names: BI-207127; BI-207127 NA; BI0207127

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Amides; Antivirals; Benzimidazoles; Carboxylic acids; Cyclobutanes; Cyclopentanes; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 31 May 2016 Boehringer Ingelheim terminates a phase I trial in Healthy volunteers in Germany prior to May 2016 (NCT01983566)
  • 01 Mar 2016 Boehringer Ingelheim terminates a phase I drug interaction study in healthy premenopausal female volunteers in Germany (NCT01941615)
  • 01 Mar 2016 Boehringer Ingelheim terminates phase I pharmacokinetics trial in patients with renal impairment, in Germany (NCT01957657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top